{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:17:36Z","timestamp":1791497856089,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19. The resulting beneficial effects of OCA on glucose and lipid metabolism and particularly hepatic inflammation make it a candidate for the treatment of a variety of conditions including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Sources of data<\/jats:title>\n                  <jats:p>In PBC patients who have not initially responded to ursodeoxycholic acid, OCA has been shown in double-blind controlled clinical trials to significantly reduce serum alkaline phosphatase. To date, OCA is the only therapy licensed by the FDA, EMA and endorsed by NICE as second line therapy for PBC.<\/jats:p>\n                  <jats:p>No medications are currently approved in Europe or the USA for the treatment of NASH.<\/jats:p>\n                  <jats:p>In recent clinical trials, OCA has been shown encouraging results by improving liver blood tests and reducing liver fibrosis with no worsening of NASH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas of agreement<\/jats:title>\n                  <jats:p>OCA is the established second line therapy for PBC in those patients who fail to adequately respond to ursodeoxycholic acid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas of controversy<\/jats:title>\n                  <jats:p>The main side effects of OCA treatment in both PBC and NASH is that of dose-dependent pruritis which can lead to treatment discontinuation in ~1\u201310% of patients. In addition, OCA-treated patients may also exhibit (reversible) alterations in serum lipid levels; most notably a small decrease in high density lipoprotein cholesterol. It is not yet known whether these changes carry a long-term cardiovascular risk in NASH.<\/jats:p>\n                  <jats:p>In addition, the relatively high cost of OCA may limit its use in cash-limited health systems.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Growing Points<\/jats:title>\n                  <jats:p>Additional clinical trials are in progress to ascertain the long-term effects of OCA on survival in PBC and NASH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas timely for developing research<\/jats:title>\n                  <jats:p>New FXR agonists with a lower rate of side effects are being developed and trialed. Combination therapy with other agents may offer increased efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bmb\/ldaa006","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T20:11:20Z","timestamp":1585080680000},"page":"95-104","source":"Crossref","is-referenced-by-count":104,"title":["Obeticholic acid\u2014a new therapy in PBC and NASH"],"prefix":"10.1093","volume":"133","author":[{"given":"Roger W","family":"Chapman","sequence":"first","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, University Offices, Wellington Square, Oxford OX1 2JD, UK"},{"name":"Translational Gastroenterology Unit, Oxford University Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7748-2165","authenticated-orcid":false,"given":"Kate D","family":"Lynch","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, University Offices, Wellington Square, Oxford OX1 2JD, UK"},{"name":"Translational Gastroenterology Unit, Oxford University Hospital, Oxford, UK"},{"name":"Faculty of Health and Medical Sciences, University of Adelaide, Port Road, Adelaide SA 5005, Australia"},{"name":"Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Port Rd, Adelaide SA 5000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"key":"2020071700041487200_ref1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"2020071700041487200_ref2","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"2020071700041487200_ref3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4254\/wjh.v11.i5.450","article-title":"Expanding etiology of progressive familial intrahepatic cholestasis","volume":"11","author":"Henkel","year":"2019","journal-title":"World J Hepatol"},{"key":"2020071700041487200_ref4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1096\/fba.2018-00046","article-title":"Bile acid receptor agonists in primary biliary cholangitis: regulation of the cholangiocyte secretome and downstream T cell differentiation","volume":"1","author":"Etherington","year":"2019","journal-title":"FASEB BioAdv"},{"key":"2020071700041487200_ref5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17512433.2015.1092381","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"9","author":"Trivedi","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2020071700041487200_ref6","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.28140","article-title":"Changing nomenclature for PBC: from \u2018cirrhosis\u2019 to \u2018cholangitis\u2019","volume":"62","author":"Beuers","year":"2015","journal-title":"Hepatology"},{"key":"2020071700041487200_ref7","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"2020071700041487200_ref8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"2020071700041487200_ref9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"EASL Clinical Practice Guidelines","year":"2017","journal-title":"J Hepatol"},{"key":"2020071700041487200_ref10","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"2020071700041487200_ref11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.12968\/hmed.2018.79.8.460","article-title":"Cost effectiveness of using ursodeoxycholic acid to treat primary biliary cholangitis","volume":"79","author":"Chapman","year":"2018","journal-title":"Br J Hosp Med"},{"key":"2020071700041487200_ref12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"2020071700041487200_ref13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"2020071700041487200_ref14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020071700041487200_ref15","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"2020071700041487200_ref16","author":"FDA Adds Black Box Warning to Intercept\u2019s Liver Disease Medicine"},{"key":"2020071700041487200_ref17","author":"FDA: Obeticholic Acid"},{"key":"2020071700041487200_ref18","doi-asserted-by":"crossref","first-page":"S636","DOI":"10.1016\/S0168-8278(16)01182-X","article-title":"SAT-357 - mitigation of pruritus during obeticholic acid treatment in patients with primary biliary cirrhosis: strategies and successes","volume":"64","author":"Mayo","year":"2016","journal-title":"J Hepatol"},{"key":"2020071700041487200_ref19","article-title":"Obeticholic acid for treating primary biliary cholangitis","author":"NICE"},{"key":"2020071700041487200_ref20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"2020071700041487200_ref21","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"2020071700041487200_ref22","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S0618-8278(19)30229-4","article-title":"LBO-05-Bezafibrate improves the effect of obeticholic acid on cholestasis in patients with primary biliary cholangitis","volume":"70","author":"Smets","year":"2019","journal-title":"J Hepatol"},{"key":"2020071700041487200_ref23","first-page":"A1380","article-title":"Obeticholic acid and bezafibrate in primary biliary cholangitis: a comparative evaluation of efficacy through real world ClinicalPractice Hepatology","author":"Culver","year":"2019"},{"key":"2020071700041487200_ref24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/flgastro-2013-100404","article-title":"Non-alcoholic fatty liver disease: a practical approach to treatment","volume":"5","author":"Dyson","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"2020071700041487200_ref25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020071700041487200_ref26","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071700041487200_ref27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","journal-title":"The Lancet"},{"key":"2020071700041487200_ref28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the Farnesoid X receptor agonist Obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"2020071700041487200_ref29","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/S0618-8278(19)30006-4","article-title":"GS-06-positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating Obeticholic acid treatment for NASH","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/133\/1\/95\/33212093\/ldaa006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/133\/1\/95\/33212093\/ldaa006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:57:45Z","timestamp":1594994265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bmb\/article\/133\/1\/95\/5818043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,13]]},"published-print":{"date-parts":[[2020,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bmb\/ldaa006","relation":{},"ISSN":["0007-1420","1471-8391"],"issn-type":[{"value":"0007-1420","type":"print"},{"value":"1471-8391","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2020,3]]}}}